CASSAVA SCIENCES INC
Clinical-stage biotech developing treatments for Central Nervous System disorders.
SAVA | US
Overview
Corporate Details
- ISIN(s):
- US69562K5065 (+1 more)
- LEI:
- Country:
- United States of America
- Address:
- 6801 N CAPITAL OF TEXAS HIGHWAY, 78731 AUSTIN
- Website:
- https://www.cassavasciences.com/
Description
Cassava Sciences, Inc. is a clinical-stage biotechnology company that develops investigational treatments for Central Nervous System (CNS) disorders. The company's primary focus is on its lead drug candidate, simufilam, a proprietary oral small molecule. Simufilam is designed to modulate the activity of the filamin A (FLNA) protein, which is involved in regulating neuronal development. The development program for simufilam targets conditions such as tuberous sclerosis complex (TSC)-related epilepsy and other mTOR pathway disorders. Preclinical studies in TSC models have shown that simufilam may reduce seizure frequency, supporting plans for future clinical trials.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all CASSAVA SCIENCES INC filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for CASSAVA SCIENCES INC
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for CASSAVA SCIENCES INC via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
